Mr has made over 2 trades of the Illumina Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 3,858 units of ILMN stock worth 122,492$ on 5 June 2017.
The largest trade he's ever made was selling 3,858 units of Illumina Inc stock on 5 June 2017 worth over 122,492$. On average, Mr trades about 643 units every 0 days since 2017. As of 5 June 2017 he still owns at least 37,440 units of Illumina Inc stock.
You can see the complete history of Mr Torres stock trades at the bottom of the page.
Jose A. Torres Jr. is the Chief Accounting Officer & VP at Illumina Inc.
Mr Jr is 46, he's been the Chief Accounting Officer & VP of Illumina Inc since . There are 20 older and 1 younger executives at Illumina Inc. The oldest executive at Illumina Inc is John Thompson, 71, who is the Lead Independent Director.
Jose's mailing address filed with the SEC is 5200 ILLUMINA WAY, , SAN DIEGO, CA, 92122.
Over the last 21 years, insiders at Illumina Inc have traded over 412,190,379$ worth of Illumina Inc stock and bought 13,386 units worth 1,243,499$ . The most active insiders traders include John Wendell Thompson、Jay T Flatley、Robert Nelsen. On average, Illumina Inc executives and independent directors trade stock every 5 days with the average trade being worth of 954,700$. The most recent stock trade was executed by Jacob Thaysen on 22 February 2024, trading 7,330 units of ILMN stock currently worth 991,676$.
at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
Illumina Inc executives and other stock owners filed with the SEC include: